INOVIO to Present at Upcoming Scientific Conference

Rhea-AI Summary

INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the World Congress of Electroporation on September 18, 2024, in Rome, Italy. Trevor Smith, VP of Preclinical R&D at INOVIO, will deliver an oral presentation titled 'Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology' at 3:20pm CET.

This presentation aligns with INOVIO's focus on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company plans to make the abstract available on its website after the presentation, providing insights into their innovative approach using CELLECTRA® electroporation technology for DNA-encoded antibodies.

News Market Reaction – INO

-0.15%

1 alert

-0.15% News Effect

On the day this news was published, INO declined 0.15%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PLYMOUTH MEETING, Pa., Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference:

World Congress of Electroporation
Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIO
Abstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology
Date and Time: September 18, 2024, 3:20pm – 3:35pm CET
Location: Rome, Italy

The abstract from the conference will be made available on INOVIO's website following the data presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302250936.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What scientific conference is INOVIO (INO) presenting at in September 2024?

INOVIO (INO) is presenting at the World Congress of Electroporation in Rome, Italy, on September 18, 2024.

Who is presenting on behalf of INOVIO (INO) at the World Congress of Electroporation?

Trevor Smith, VP of Preclinical R&D at INOVIO, will be delivering the oral presentation at the conference.

What is the title of INOVIO's (INO) presentation at the World Congress of Electroporation?

The presentation is titled 'Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology'.

When and where will INOVIO (INO) make the abstract from the conference available?

INOVIO will make the abstract available on their website following the data presentation at the conference.

What are the main areas of focus for INOVIO's (INO) DNA medicines?

INOVIO focuses on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.